Active rheumatoid arthritis

Risk of treatment termination compared[1]



Compared with gold, d-penicillamine and levamisole in the treatment of active rheumatoid arthritis, Plaquenil (hydroxychloroquine) showed the lowest frequency of treatment termination due to side effects.[1]

"Fewest adverse reactions occurred with hydroxychloroquine (Plaquenil) at all times during drug treatment."[1]

Also, in a study of 311 patients treated with Plaquenil (6.5 mg/kg/day) no eye lesions were recorded[2] – confirming the consensus of recent studies that problems can usually be avoided by rigid adherence to dosage recommendations with regular ophthalmological screening.[3,4]

Plaquenil

hydroxychloroquine

For prescribing information see overleaf.

SRXL

First in the second line

1. J. Rheumatol. 1980; 7: 825-830. 2. Am J Med. 1983; 75(1A): 40-45. 3. Am J Med. 1983; 75(1A): 1-4. 4. Am J Med. 1983; 75(1A): 25-34.